Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 99-107 , March 2007

New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients

  • John R. Wingard, MD (Director)

      Affiliations

    • Corresponding Author InformationTel.: +1 352 273 8010; Fax: +1 352 273 8109.

References 

  1. Pfaller MA, Pappas PG, Wingard JR. Invasive fungal pathogens: current epidemiological trends. Clinical Infectious Diseases. 2006;43:S3–S14
  2. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrobial Agents and Chemotherapy. 2005;49:3640–3645
  3. Greene RE, Schlamm HT, Oestmann JW et al. Imaging findings in acute invasive pulmonary aspergillosis: clinical significance of the halo sign. Clinical Infectious Diseases [in press].
  4. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. The American Journal of Medicine. 1982;72:101–111
  5. EORTC International Antimicrobial Therapy Cooperative Project Group. Empiric antifungal therapy in febrile granulocytopenic patients. The American Journal of Medicine. 1989;86:668–672
  6. Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clinical Infectious Diseases. 2004;39(supplement 1):S38–S43
  7. De Pauw BE. Between over- and undertreatment of invasive fungal disease. Clinical Infectious Diseases. 2005;41:1251–1253
  8. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. Journal of Clinical Oncology. 1997;15:139–147
  9. Greene R. The radiological spectrum of pulmonary aspergillosis. Medical Mycology. 2005;43(supplement 1):S147–S154
  10. Alexander BD, Pfeiffer RM. Contemporary tools for diagnosis and managment of invasive mycoses. Clinical Infectious Diseases. 2006;43:S15–S27
  11. Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. The Journal of Infectious Diseases. 2004;190:641–649
  12. Hope WW, Walsh TJ, Denning DW. Laboratory diagnosis of invasive aspergillosis. The Lancet Infectious Diseases. 2005;5:609–622
  13. Odabasi Z, Mattiuzzi G, Estey E, et al. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clinical Infectious Diseases. 2004;39:199–205
  14. Ostrosky-Zeichner L, Alexander BD, Kett DH, et al. Multicenter clinical evaluation of the (1–>3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clinical Infectious Diseases. 2005;41:654–659
  15. Mennink-Kersten MA, Donnelly JP, Verweij PE. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. The Lancet Infectious Diseases. 2004;4:349–357
  16. Maertens J, Theunissen K, Verhoef G, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clinical Infectious Diseases. 2005;41:1242–1250
  17. Hebart H, Klingspor L, Klingebiel T, et al. PCR-based liposomal amphotericin B treatment following allogeneic stem cell transplantation is a safe treatment strategy: Preliminary results of a prospective study. Blood. 2004;104:59a;(abstract)
  18. Bow EJ, Laverdiere M, Lussier N, et al. Antifungal prophylaxis for severely neutropenic chemotherapy recipients: a meta analysis of randomized-controlled clinical trials. Cancer. 2002;94:3230–3246
  19. Kanda Y, Yamamoto R, Chizuka A, et al. Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer. 2000;89:1611–1625
  20. Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clinical Infectious Diseases. 2002;34:909–917
  21. Grow WB, Moreb JS, Roque D, et al. Late onset of invasive aspergillus infection in bone marrow transplant patients at a university hospital. Bone Marrow Transplantation. 2002;29:15–19
  22. Winston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Annals of Internal Medicine. 2003;138:705–713
  23. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004;103:1527–1533
  24. Cornely O, Maertens J, Winston D, et al. Posaconazole vs standard azole (FLU/ITRA) therapy for prophylaxis of invasive fungal infections (IFIs) among high-risk neutropenic patients: results of a randomized, multicenter trial. Blood. 2005;106:524a;(abstract)
  25. Ullmann AJ, Lipton JH, Vesole DH, et al. A multicenter trial of oral posaconazole vs fluconazole for the prophylaxis of invasive fungal infections in recipients of allogeneic hematopoietic stem cell transplantation with graft-vs-host disease. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2005;(abstract M-716)
  26. Wingard JR. Design issues in a prospective randomized double-blinded trial of prophylaxis with fluconazole versus voriconazole after allogeneic hematopoietic cell transplantation. Clinical Infectious Diseases. 2004;39(supplement 4):S176–S180
  27. van Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clinical Infectious Diseases. 2004;39:1407–1416
  28. Mattiuzzi GN, Alvarado G, Giles FJ, et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrobial Agents and Chemotherapy. 2006;50:143–147
  29. Penack O, Reinwald M, Schmidt-Hieber M, et al. Low dose liposomal amphotericin B (L-AmB) as prophylaxis of invasive fungal infections (IFI) in patients (pts) with prolonged neutropenia (N): results from a phase-III trial. Interscience Conference on Antimicrobial Agents and Chemotherapy. 2005;(abstract M-975)
  30. Mattiuzzi GN, Estey E, Raad I, et al. Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome. Cancer. 2003;97:450–456
  31. Kontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. The Journal of Infectious Diseases. 2005;191:1350–1360
  32. Mattner F, Weissbrodt H, Strueber M. Two case reports: fatal Absidia corymbifera pulmonary tract infection in the first postoperative phase of a lung transplant patient receiving voriconazole prophylaxis, and transient bronchial Absidia corymbifera colonization in a lung transplant patient. Scandinavian Journal of Infectious Diseases. 2004;36:312–314
  33. Imhof A, Balajee SA, Fredricks DN, et al. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clinical Infectious Diseases. 2004;39:743–746
  34. Marty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem-cell transplants. The New England Journal of Medicine. 2004;350:950–952
  35. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clinical Infectious Diseases. 2004;39:584–587
  36. Kobayashi K, Kami M, Murashige N, et al. Breakthrough zygomycosis during voriconazole treatment for invasive aspergillosis. Haematologica. 2004;89:ECR42
  37. Vigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clinical Infectious Diseases. 2005;40:e35–e37
  38. Wingard JR. Zygomycosis: epidemiology and treamtnet options. Johns Hopkins Advanced Studies in Medicine. 2006;6:S526–S530
  39. Bennett JE, Dismukes WE, Duma RJ, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. The New England Journal of Medicine. 1979;301:126–131
  40. Rex JH, Bennett JE, Sugar AM, et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. The New England Journal of Medicine. 1994;331:1325–1330
  41. Schaffner A, Frick PG. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis. The Journal of Infectious Diseases. 1985;151:902–910
  42. Steinbach WJ. Combination antifungal therapy for invasive aspergillosis: utilizing new targeting strategies. Current Drug Targets Infectious Disorders. 2005;5:203–210
  43. Wheat LJ. Combination therapy for aspergillosis: is it needed, and which combination?. The Journal of Infectious Diseases. 2003;187:1831–1833
  44. Johnson MD, MacDougall C, Ostrosky-Zeichner L, et al. Combination antifungal therapy. Antimicrobial Agents and Chemotherapy. 2004;48:693–715
  45. Kontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: the prospects of combination therapy. British Journal of Haematology. 2004;126:165–175
  46. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. Combination treatment of invasive fungal infections. Clinical Microbiology Reviews. 2005;18:163–194
  47. Cuenca-Estrella M. Combinations of antifungal agents in therapy–what value are they?. The Journal of Antimicrobial Chemotherapy. 2004;54:854–869
  48. Singh N, Limaye AP, Forrest G, et al. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation. 2006;81:320–326
  49. Aliff TB, Maslak PG, Jurcic JG, et al. Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin. Cancer. 2003;97:1025–1032
  50. Kontoyiannis DP, Hachem R, Lewis RE, et al. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98:292–299
  51. Marr KA, Boeckh M, Carter RA, et al. Combination antifungal therapy for invasive aspergillosis. Clinical Infectious Diseases. 2004;39:797–802
  52. Caillot D, Thiebault A, Herbrecht R, et al. Liposomal amphotericin B in combination with caspofungin versus liposomal amphotericin B high dose regimen for the treatment of invasive aspergillosis in immunocompromised patients: randomized pilot study (Combistrat trial). Focus on Fungal Infections. 2006;16:174;(abstract P-004)

PII: S1521-6926(06)00088-0

doi: 10.1016/j.beha.2006.11.008

Best Practice & Research Clinical Haematology
Volume 20, Issue 1 , Pages 99-107 , March 2007

Article Tools

* Image Usage & Resolution